Brighton Jones LLC Buys New Shares in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Brighton Jones LLC bought a new position in SPDR S&P Biotech ETF (NYSEARCA:XBI) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 2,240 shares of the exchange traded fund’s stock, valued at approximately $208,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. ICA Group Wealth Management LLC purchased a new position in SPDR S&P Biotech ETF during the fourth quarter valued at $27,000. Scarborough Advisors LLC bought a new stake in shares of SPDR S&P Biotech ETF in the fourth quarter worth about $32,000. BOCHK Asset Management Ltd purchased a new stake in shares of SPDR S&P Biotech ETF in the fourth quarter worth about $36,000. ORG Partners LLC purchased a new stake in shares of SPDR S&P Biotech ETF in the second quarter worth about $40,000. Finally, Vima LLC bought a new position in SPDR S&P Biotech ETF during the fourth quarter valued at approximately $45,000.

SPDR S&P Biotech ETF Stock Performance

NYSEARCA XBI opened at $101.61 on Monday. The stock has a 50 day moving average price of $99.03 and a 200-day moving average price of $93.90. SPDR S&P Biotech ETF has a one year low of $63.80 and a one year high of $103.52. The company has a market capitalization of $7.74 billion, a P/E ratio of 11.47 and a beta of 1.11.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.